Srebrnjak Children's Hospital

Their core work

Srebrnjak Children's Hospital is a specialized pediatric clinical institution in Zagreb, Croatia, that contributes clinical expertise and patient-based data to European research consortia. Their research work focuses on two distinct but complementary areas: medication safety during pregnancy and early childhood (pharmacovigilance), and the health effects of environmental contaminants — particularly microplastics — on children and vulnerable populations. As a hospital, they provide what pure research institutes cannot: access to real patients, clinical validation of biomarkers, and the ability to observe how contaminants and drugs affect developing bodies in real-world conditions. Their value in EU projects is as a clinical anchor that translates laboratory findings into patient-relevant outcomes.

What they specialise in

How they've shifted over time

Their H2020 participation began around 2019 with a pharmacovigilance focus — specifically monitoring how medicines affect pregnant women and newborns, contributing to a biobank and outcome measures infrastructure. By 2021, their focus had shifted markedly toward environmental health: microplastics, dietary contaminant absorption, and the toxicological consequences of environmental exposure on children. The common thread is vulnerable pediatric and perinatal populations, but the external driver changed from drug safety to environmental pollution — reflecting a broader European research priority shift. The trajectory suggests a hospital that is deliberately expanding its research identity from clinical pharmacology into environmental pediatric medicine.

They are moving toward environmental toxicology in pediatric populations — a fast-growing field — making them a likely target partner for future consortia addressing children's exposure to pollutants, food contaminants, and climate-related health risks.

How they like to work

Srebrnjak has never led an H2020 project — both participations are as a clinical partner or third-party contributor, which is typical for hospitals in research consortia. Their strength is what they bring to a larger team: pediatric patients, clinical protocols, and real-world validation capacity. With 75 unique partners across 22 countries from just two projects, they have been embedded in very large multi-site European consortia — suggesting they are comfortable operating as one clinical node among many rather than steering the scientific agenda.

Despite only two projects, Srebrnjak has connected with 75 unique consortium partners across 22 countries — a sign of membership in broad, well-networked pan-European research programs. Their geographic reach is genuinely European, with no apparent regional concentration beyond being part of major RIA consortia.

What sets them apart

Srebrnjak is one of very few pediatric hospitals in Southeast Europe with active H2020 research participation, giving it a rare combination of clinical access and EU research credentials in a region underrepresented in European health consortia. For projects requiring clinical validation in children — drug safety, contaminant exposure, allergy, or respiratory outcomes — they offer something most research institutes cannot: actual pediatric patients and ethical approval infrastructure. A consortium builder looking for a Croatian or Balkan clinical partner in the health or environmental toxicology space has very few credible alternatives.

Highlights from their portfolio

• Imptox
  Their only funded participant role (EUR 401,555), this project addresses one of the most urgent emerging health concerns in Europe — the human health effects of micro- and nanoplastics — with the hospital contributing clinical pediatric data on absorption, allergy, and digestion.
• ConcePTION
  A flagship EU pharmacovigilance initiative running 2019–2024, ConcePTION involved dozens of institutions building shared pregnancy safety data infrastructure — Srebrnjak's inclusion signals recognized clinical credibility even in a third-party role.